According to a recent study among patients infected with COVID-19 in the Hubei province of China, nearly 49% of people were hospitalised with gastrointestinal symptoms such as stomach cramps, pain, diarrhea and vomiting.
The course of disease was also more severe than of those with just respiratory symptoms.
“The public and patients should understand that some GI symptoms (such as loose stools up to 3 times per day) may accompany respiratory complaints in almost half of patients. Physicians evaluating new GI complaints should consider COVID-19 and take appropriate precautions,”
Arun Swaminath MD, FAGG, Associate Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell, Director Inflammatory Bowel Disease Program, Lenox Hill Hospital, Northwell Health.
Swaminath also qualified that “no patients with underlying bowel diseases were included, so we don’t know how COVID-19 affects patients with underlying bowel diseases, such as Crohn’s disease and ulcerative colitis.”
According to this study, the patients with GI symptoms also had an adverse outcome and higher death risk than patients without GI symptoms.
Russian Ministry of Health included enterosorbents (Enterosgel®) in the treatment protocol for patients infected with Coronavirus.
A sufficient amount of fluid (2.5-3.5 liters per day or more, if there
are no contraindications for somatic pathology). In cases of severe
intoxication, abdominal pain, nausea and/or vomiting, edematous syndrome,
which impedes fluid intake, oral intestinal adsorbents (Enterosgel®) are